| Overview |
| bs-1684R-HRP |
| C-SKI/v-SKI Polyclonal Antibody, HRP Conjugated |
| WB, ELISA, IHC-P, IHC-F |
| Human, Mouse, Rat, Dog, Cow, Horse, Chicken |
| Specifications |
| HRP |
| Rabbit |
| KLH conjugated synthetic peptide derived from human C-SKI |
| 551-650/728 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 6497 |
| Nucleus |
| Sloan-kettering viral oncogene homolog; Avian sarcoma viral v ski oncogene homolog; C oncogene; C ski; Ski oncogene; Ski oncoprotein; SKV; v ski avian sarcoma viral oncogene homolog; v ski sarcoma viral oncogene homolog; v-ski sarcoma viral oncogene homolog; SKI_HUMAN. |
| SKI is a nuclear protein that forms homodimers and heterodimers and binds to DNA to function as transcriptional activators and repressors. The SKI oncoprotein dramatically affects cell growth, differentiation, and/or survival. SKI was shown to act in distinct signaling pathways including those involving nuclear receptors, transforming growth factor beta, and tumor suppressors. SKI inhibits transforming growth factor-beta (TGF-beta) signaling through interaction with Smad proteins. SKI represses Smad-mediated transcriptional activation, probably through its action as a transcriptional co-repressor. SKI also inhibits TGF-beta-induced downregulation of genes such as c-myc. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
Powered by Bioz